Neutra Corp. (NTRR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Neutra Corp. (NTRR) trades at $0.0002. Neutra Corp. is a biotechnology company focused on researching, developing, and providing hemp-based nutraceutical products, including CBD sports creams. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NTRR: NTRR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NTRR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NTRR.
How is this calculated? →Neutra Corp. (NTRR) Healthcare & Pipeline Overview
Neutra Corp. is a biotechnology company specializing in hemp-based nutraceutical products, including CBD sports creams, operating in the competitive healthcare sector. With a focus on research and development, Neutra Corp. aims to capitalize on the growing demand for alternative wellness solutions, but faces challenges common to OTC-listed companies.
What Is the Investment Thesis for NTRR?
Neutra Corp. presents a speculative investment opportunity within the hemp-based nutraceutical market. With a market capitalization of $0.00B and a negative P/E ratio of -0.16, the company's financial performance indicates significant challenges. A gross margin of 54.2% suggests potential in product profitability, but a negative profit margin of -158.5% highlights substantial operational inefficiencies. Growth catalysts include potential regulatory changes favoring hemp-based products and successful product development initiatives. The company's small size and OTC listing introduce significant risks, including liquidity constraints and disclosure limitations. Investors should carefully consider these factors and conduct thorough due diligence before investing in NTRR.
Based on FMP financials and quantitative analysis
NTRR Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited financial resources.
- P/E Ratio of -0.16 reflects negative earnings, suggesting the company is not currently profitable.
- Gross Margin of 54.2% demonstrates potential profitability at the product level, before considering operating expenses.
- Profit Margin of -158.5% reveals significant operational losses, indicating challenges in managing expenses.
- Beta of 1.48 suggests the stock is more volatile than the overall market, implying higher risk.
Who Are NTRR's Competitors?
NTRR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NTRR's Key Strengths?
Focus on hemp-based nutraceuticals.
- Proprietary product formulations.
- Established brand reputation within its niche.
- Lean operational structure.
What Are NTRR's Weaknesses?
Limited financial resources.
- Negative profitability.
- Small market capitalization.
- OTC listing introduces liquidity and disclosure risks.
What Could Drive NTRR Stock Higher?
Potential regulatory changes favoring hemp-based products could expand market opportunities.
- Research and development efforts to create new and innovative hemp-based nutraceutical products.
- Expansion of online sales and marketing initiatives to reach a broader audience.
What Are the Key Risks for NTRR?
Intense competition in the nutraceutical market could limit market share and profitability.
- Regulatory uncertainty surrounding hemp-based products could negatively impact operations.
- Limited financial resources could hinder growth and expansion efforts.
- Adverse publicity or product recalls could damage brand reputation and sales.
- OTC listing introduces liquidity and disclosure risks.
What Are the Growth Opportunities for NTRR?
- Expansion of Product Line: Neutra Corp. can expand its product line to include a wider range of hemp-based nutraceuticals, such as edibles, tinctures, and topicals. The global nutraceutical market is projected to reach $441.7 billion by 2026, offering significant opportunities for companies with innovative products. Successful product diversification could drive revenue growth and increase market share for Neutra Corp. Timeline: 1-2 years.
- Strategic Partnerships: Neutra Corp. can form strategic partnerships with established retailers and distributors to expand its market reach and distribution network. Partnering with major retailers could provide access to a larger customer base and increase brand visibility. The retail distribution of nutraceuticals is a key driver of market growth. Timeline: 1 year.
- Online Sales and Marketing: Neutra Corp. can invest in online sales and marketing initiatives to reach a broader audience and drive online sales. The e-commerce channel is experiencing rapid growth in the nutraceutical market, offering companies the opportunity to reach consumers directly. Effective online marketing campaigns and a user-friendly e-commerce platform could significantly boost sales. Timeline: Ongoing.
- Research and Development: Neutra Corp. can invest in research and development to develop new and innovative hemp-based nutraceutical products. The nutraceutical market is driven by innovation and the introduction of new products with proven health benefits. Investing in R&D could lead to the development of proprietary formulations and a competitive advantage. Timeline: Ongoing.
- Regulatory Changes: Potential changes in regulations surrounding hemp-based products could create new opportunities for Neutra Corp. As regulations become more favorable, the company could expand its operations and market its products more widely. Monitoring regulatory developments and adapting to changes is crucial for success in this industry. Timeline: Ongoing.
What Are NTRR's Competitive Advantages?
- Focus on hemp-based nutraceuticals provides a niche market position.
- Proprietary formulations and product development efforts.
- Established brand reputation within its target market.
What Does NTRR Do?
Neutra Corp., incorporated in 2011 and based in Sugar Land, Texas, is a biotechnology company engaged in the research, development, and provision of hemp-based nutraceutical products. The company's primary focus is on CBD sports creams and other related products, targeting consumers interested in alternative wellness solutions. Neutra Corp. aims to leverage the growing market for hemp-derived products, positioning itself as a provider of innovative nutraceuticals. Since its inception, Neutra Corp. has navigated the evolving regulatory landscape surrounding hemp and CBD products. The company's strategy involves developing and marketing products that comply with current regulations while exploring opportunities for expansion within the nutraceutical market. Neutra Corp. operates with a relatively small team of 15 employees, indicating a lean operational structure. The company's headquarters in Houston reflects its focus on the U.S. market, where it aims to establish a strong presence in the hemp-based nutraceutical sector. Neutra Corp.'s success depends on its ability to innovate, maintain regulatory compliance, and effectively market its products to a growing consumer base. The company faces competition from other players in the nutraceutical market, including those with greater resources and established distribution networks. Neutra Corp.'s focus on hemp-based products differentiates it from some competitors, but also exposes it to specific regulatory and market risks associated with this category.
What Products and Services Does NTRR Offer?
- Researches hemp-based nutraceutical products.
- Develops hemp-based nutraceutical products.
- Provides hemp-based nutraceutical products.
- Offers CBD sports creams.
- Focuses on alternative wellness solutions.
- Operates in the biotechnology industry.
How Does NTRR Make Money?
- Develops and markets hemp-based nutraceutical products.
- Generates revenue through the sale of CBD sports creams and related products.
- Focuses on direct-to-consumer sales through online channels.
What Industry Does NTRR Operate In?
Neutra Corp. operates in the biotechnology industry, specifically within the rapidly evolving nutraceutical market. The nutraceutical market is experiencing growth driven by increasing consumer interest in health and wellness products, particularly those derived from natural sources like hemp. However, the industry is also characterized by intense competition and regulatory uncertainty, especially concerning hemp-based products. Neutra Corp. faces competition from established nutraceutical companies, as well as smaller players focused on specific niches. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and effectively market to its target audience.
Who Are NTRR's Key Customers?
- Individuals seeking alternative wellness solutions.
- Athletes and active individuals looking for pain relief and recovery products.
- Consumers interested in hemp-based products.
Company Profile
Neutra Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Sydney Jim. NTRR has traded publicly since 2011.
Key Financial Metrics
NTRR trades at a trailing price-to-earnings ratio of 0.28, below the Healthcare sector average of ~23x. Its free cash flow yield is 25.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.18 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Neutra Corp.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 24.19 places it in the safe zone, indicating low near-term bankruptcy risk.
NTRR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Focus on hemp-based nutraceuticals.
- Proprietary product formulations.
- Established brand reputation within its niche.
- Lean operational structure.
Bear Case
- Limited financial resources.
- Negative profitability.
- Small market capitalization.
- OTC listing introduces liquidity and disclosure risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NTRR Latest News
No recent news available for NTRR.
NTRR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTRR.
Price Targets
Wall Street price target analysis for NTRR.
NTRR MoonshotScore
What does this score mean?
The MoonshotScore rates NTRR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sydney Jim
CEO
Sydney Jim serves as the CEO of Neutra Corp., overseeing the company's strategic direction and operations. Information regarding Sydney Jim's background and previous experience is not available in the provided context. Therefore, a detailed professional history cannot be provided. He is responsible for managing the company's 15 employees and driving its growth in the hemp-based nutraceutical market.
Track Record: Due to the limited information available, Sydney Jim's specific achievements and strategic decisions as CEO of Neutra Corp. cannot be detailed. His tenure and impact on company milestones are not specified in the provided data.
NTRR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Neutra Corp. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited liquidity, lack of transparency, and increased volatility.
- OTC Tier: OTC Other
- Limited liquidity due to OTC Other listing.
- Lack of transparency due to unknown disclosure status.
- Potential for price manipulation and fraud.
- Higher volatility compared to stocks listed on major exchanges.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or press releases about the company.
- Company has been in operation since 2011.
- Focus on a growing market (hemp-based nutraceuticals).
- Gross margin of 54.2% suggests potential for profitability.
- Company has a website and online presence.
- Company is based in the United States.
NTRR Healthcare Stock FAQ
What does Neutra Corp. do?
Neutra Corp. is a biotechnology company that researches, develops, and provides hemp-based nutraceutical products, including CBD sports creams. The company focuses on offering alternative wellness solutions to consumers interested in natural and hemp-derived products. Neutra Corp. operates in the evolving nutraceutical market, aiming to capitalize on the growing demand for hemp-based health and wellness products.
What do analysts say about NTRR stock?
There is currently no available analyst coverage for NTRR stock. Given its OTC listing and small market capitalization, Neutra Corp. is not widely followed by analysts. Investors should conduct their own thorough research and due diligence before investing in NTRR. Key valuation metrics to consider include the company's market capitalization, P/E ratio, gross margin, and profit margin.
What are the main risks for NTRR?
Neutra Corp. faces several risks, including intense competition in the nutraceutical market, regulatory uncertainty surrounding hemp-based products, limited financial resources, and potential adverse publicity or product recalls. As an OTC-listed company, NTRR also faces liquidity and disclosure risks. The company's negative profitability and small market capitalization further increase the risk for investors. Investors should carefully consider these risks and conduct thorough due diligence before investing in NTRR.
What are the key factors to evaluate for NTRR?
Evaluate NTRR on fundamentals, analyst consensus, and risk factors. Neutra Corp. presents a speculative investment opportunity within the hemp-based nutraceutical market. Not financial advice.
How frequently does NTRR data refresh on this page?
NTRR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NTRR's recent stock price performance?
Neutra Corp. (NTRR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on hemp-based nutraceuticals. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NTRR overvalued or undervalued right now?
Neutra Corp. (NTRR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NTRR before investing?
Before investing in Neutra Corp. (NTRR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Neutra Corp. due to its OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.